Alder agrees potential $1 billion deal with BMS for rheumatoid arthritis treatment
This article was originally published in Scrip
Alder Biopharmaceuticals has signed a licensing agreement with Bristol-Myers Squibb for its lead programme ALD518 that could be worth in excess of $1 billion for the small US biotechnology company.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.